ArticleMolecular cancer therapeutics2025

A B7-H3-Targeted CD28 Bispecific Antibody Enhances the Activity of Anti-PD-1 and CD3 T-cell Engager Immunotherapies.

Gregory L Moore et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.